ONCY Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ONCY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Oncolytics Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.35 |
| 52 Week High | CA$1.53 |
| 52 Week Low | CA$0.33 |
| Beta | 1.19 |
| 1 Month Change | -36.91% |
| 3 Month Change | -52.97% |
| 1 Year Change | -67.26% |
| 3 Year Change | -68.02% |
| 5 Year Change | -84.08% |
| Change since IPO | -99.29% |
Recent News & Updates
Shareholder Returns
| ONCY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.5% | 1.7% | 0.7% |
| 1Y | -67.3% | -10.7% | 12.6% |
Return vs Industry: ONCY underperformed the US Biotechs industry which returned -11.5% over the past year.
Return vs Market: ONCY underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| ONCY volatility | |
|---|---|
| ONCY Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ONCY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ONCY's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 28 | Wayne Pisano | oncolyticsbiotech.com |
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
Oncolytics Biotech Inc. Fundamentals Summary
| ONCY fundamental statistics | |
|---|---|
| Market cap | US$29.78m |
| Earnings (TTM) | -US$22.96m |
| Revenue (TTM) | n/a |
Is ONCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCY income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$31.50m |
| Earnings | -CA$31.50m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ONCY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/03 06:17 |
| End of Day Share Price | 2025/06/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncolytics Biotech Inc. is covered by 22 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Loe | Byron Capital Markets |
| Douglas Loe | Cantor Fitzgerald Canada Corporation |
| Douglas Loe | Echelon Wealth Partners Inc. |